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BACKGROUND Arterial aneurysms (An) are traditionally treated sur-
gically, but more and more by interventional procedures with a high
technical success rate, but some problems are not solved like pro-
tection of aneurysm rupture, endoleaks, stent thrombosis, collateral
branch thrombosis. We used a new concept of stent, the Multilayer
Flow Modulator (MFM*) to treat An. and try to avoid some drawbacks
encountered with endografts.
METHODS This MFM* is a 3 Dimensional braided tube made of several
interconnected layers without any covering. Our earliest in vitro
(theorical simulation), computerized Fluid dynamics, Molecular
Modelization and in vivo tests demonstrated that this MFM* reduces
the velocity in the aneurismal sac up to 90% by modifying the he-
modynamic conditions. A saccular aneurysm without collateral
branch will thrombose quickly. If a collateral branch is present the
ﬂow is directed towards this branch leading to shrinkage of the
aneurysm. Animal experiments show excellent results. Moreover, as
demonstrated in animal and human studies this MFM* preserves the
collateral branches allowing the possibility to cover any artery
without compromising the ﬂow (renal, digestive arteries, supra aortic
vessels.)
RESULTS 44 peripheral An. (iliac:23, femoral:1, popliteal:5, renal:8,
mesenteric:2, carotid: 2, Subclavian : 2, Caeliac trunk :1) were treated
with the MFM* (male:31, mean age 62þ/-8 y) (57 stents ⌀ 5 to 14 mm;
length 40 to 120 mm) were implanted to treat these aneurysms, by
femoral approach (43 cases), brachial approach (1 case), Technical
success in all patients. No complications. All An. thrombosed with
diameter reduction in some pts. The thrombosis could take several
weeks depending on the importance of collateral branches. 6 month to
36 month follow up will be presented and we will discuss the time
needed to achieve exclusion of the An. All the side branches remained
patent.
CONCLUSIONS A new concept of stent, the MFM* (without any
covering) is developed to treat An. It opens a new approach to treat
peripheral An. avoiding most of the complications encountered with
current endovascular techniques. The results obtained seem prom-
ising. A larger study is ongoing.
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BACKGROUND Thoraco Abdominal Aortic Aneurysms (TAAA) and
Abdominal Aortic Aneurysms (AAA) are traditionally treated surgi-
cally, but more and more by interventional procedures (endografts,
fenestrated, branched grafts, chimney techniques). We used a new
concept of stent, the Multilayer Stent Flow Modulator (M.F.M) to treat
these aneurysms (A) and try to avoid some major complications.
METHODS This selfexpandable M.F.M is a 3 D braided tube made of
several interconnected layers without any covering. We will explain
and demonstrate the key principles of the stent leading to thrombosis,
shrinkage of the A, eliminating the risk of rupture. The M.F.M pre-
serves the collateral branches allowing the possibility to cover any
artery without compromising the ﬂow (renal, digestive arteries, supra
aortic vessels.).Moreover it increases the ﬂow by 25% in Renal Ar-
teries and 23% in Supra Aortic branches
RESULTS 10 TAAA, 8 AAA (7 extended to both iliac arteries) treated
with MFM in very high risk patients. 53 MFM implanted (1 to 5 per pt).
o Technical success: 100% o At 30 days: no neurological complication,
branch patency 100%, no death o During the follow up we had 3
deaths not device related. CT scan control performed at 1, 3, 6, 12, 18
months with calculation of A. Diameters and Volumes. o All collateral
branches remain patent and we observed a progressive thrombosis
and shrinkage of the aneurysmal sac depending on the size of the
collaterals. Some patients developed a thrombus after 1 month, someafter 6 months and some even after 18 months. o A signiﬁcant mean
diameter reduction was observed between baseline and 6 months:
15,99 mm reduction for the transversal diameter, 12,75 mm for the
antero posterior diameter in the TAAA group. o Overtime the ratio
thrombus volume / Total Volume is increasing and the ratio Residual
Flow Volume / Total Volume is decreasing. The problems of throm-
bosis, shrinkage and volume reduction of the aneurysmal sac will be
discussed. Long-term follow-up (5 years)will be presented The com-
plications rates with M.F.M appear lower in comparison with current
endovascular techniques, and with surgery.
CONCLUSIONS The M.F.M represents an alternative to current de-
vices to treat TAAA and AAA. It is a safe procedure with a low
complication rate. The ﬁrst results are promising. A larger study is
ongoing.
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BACKGROUND Renal Artery Aneurysms (RAAs) can be surgically
treated but due to high risk, endovascular procedures have been
proposed (coils, graft...). All these techniques have some drawbacks,
potential complications and contraindications. We propose a new
technique: the Multilayer Flow Modulator (MFM*), a self expandable.
METHODS This MFM* is a 3D braided tube made of several inter-
connected layers without any covering. Our earliest tests, in vitro
(theorical simulation computerized Fluid dynamics, Molecular
Modelization) & in vivo. demonstrate that this MFM* reduces the
velocity in the aneurismal sac up to 90% by modifying the hemody-
namic conditions.. A saccular aneurysm (A.) without collateral branch
will thrombose quickly. If a collateral branch is present the ﬂow is
directed towards this branch leading to shrinkage of the aneurysm. In
fusiform A. the ﬂow is laminated, the vortexes eliminated, eliminating
the risk of rupture. Animal experiments show excellent results.
Moreover, as demonstrated in animal and human studies this MFM
preserves the collateral branches and increases the ﬂow in them,
allowing the possibility to cover any artery without compromising the
ﬂow.
RESULTS 9 RAAs (right: 6, left: 3) in 9 pts (male: 4) mean age 58 y.
treated with MFM* 7 pts had atheromatous disease, 2 a ﬁbromuscular
dysplasia. One pt had a solitary kidney. All these pts had hyperten-
sion. 11 MFM*(⌀: 5 to 7 mm, length 30 to 60 mm) loaded in a 6 F sheath
implanted by femoral approach through 8 F guiding catheter. These
stents covered major renal branches without compromising the ﬂow.
Technical success: 100%. No complications. Immediately: important
reduction of the velocities inside the aneurismal sac. 6 to 36 month
follow up will be presented. All aneurysms thrombosed with diameter
reduction in some pts. The thrombosis could take several weeks
depending on the importance of collateral branches. All the side
branches remain patent.
CONCLUSIONS The MFM* is a new technique which seems promising
to treat RAAs. Collateral branches can be covered without compro-
mising the ﬂow and risk of renal infarction. It is a safe procedure with
a very low complications rate. Larger study is ongoing.
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BACKGROUND To evaluate the safety and efﬁciency of vertebral an-
gioplasty and stenting (VAS) in symptomatic patients.
